Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market
Ollin Biosciences officially launched on September 17, 2025, with $100 million in funding from Arch Venture Partners, Mubadala Capital, and Monograph Capital.
The company is led by Dr. Jason Ehrlich, former Genentech ophthalmologist pivotal in Roche’s Vabysmo development.
Ollin’s lead asset, OLN324, is a clinical-stage bispecific antibody targeting VEGF and Ang2—the same targets as Roche’s blockbuster drug Vabysmo.
OLN324 is currently in a Phase 1b head-to-head trial against Vabysmo in 150 patients with wet AMD or diabetic macular edema, with top-line data expected in Q1 2026.
Ollin touts OLN324’s higher Ang2 potency and smaller molecular size, which may enable better tissue penetration and efficacy after injection.
Direct comparison with Roche’s Vabysmo at this early stage is unusual and reflects Ollin’s aggressive strategy to establish competitiveness in the eye disease market.
Ollin views Vabysmo as the ‘current standard of care’ and aims to surpass it with its pipeline molecules.
The launch and trial signal a potential new front in the intensifying biotech rivalry for dominance in the lucrative retinal disease sector.